Amikacin liposome Inhalation and Pulmonary disease
Result of checking the interaction of drug Amikacin liposome Inhalation and disease Pulmonary disease for safety when used together.
When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.
Consumer:Higher frequency of exacerbations of underlying pulmonary disease has been reported with amikacin liposome treatment. Monitor closely patients with pulmonary impairment and treat as medically appropriate if this occurs during treatment with amikacin liposome. Pre- treatment with short-acting selective beta- 2 agonists should be considered for patients with known hyperreactive airway disease, chronic obstructive pulmonary disease, asthma, or bronchospasm.
Generic Name: amikacin liposome
Brand Name: Arikayce
Synonyms: Amikacin liposome, Amikacin (Oral Inhalation)